BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Scholar Rock Stock Surges on Analyst Optimism for SMA Drug
Scholar Rock Stock Surges on Analyst Optimism for SMA Drug
24
3
BTCCSquare news:
Scholar Rock (SRRK) shares climbed over 6% Monday, outpacing the broader market's modest gains, after Leerink Partners initiated coverage with an outperform rating and a $51 price target. The bullish outlook hinges on apitegromab, the biotech's experimental spinal muscular atrophy therapy currently under FDA and EMA review.
Analyst Mani Foroohar highlighted Scholar Rock's rare disease commercialization expertise as a key differentiator. Regulatory approvals could position the company for significant equity growth, with the price target implying 51% upside from current levels.
By:
